A randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results

Jürgen K. Rockstroh, Edwin Dejesus, Keith Henry, Jean Michel Molina, Joseph Gathe, Srinivasan Ramanathan, Xuelian Wei, Andrew Plummer, Michael Abram, Andrew K. Cheng, Marshall W. Fordyce, Javier Szwarcberg

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Fingerprint Dive into the research topics of 'A randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results'. Together they form a unique fingerprint.

Medicine & Life Sciences